No Data
[Popular Industry] The Global competition accelerates as China's Innovative Drugs Industry enters a new cycle.
King Wu Finance | The Global Innovative Drugs research and development landscape is undergoing profound changes. The latest assessment by McKinsey shows that the USA dominates the leading tier of global drug development, accounting for over half of the world's new drug research, while China's new drug development has entered the forefront of the global second tier. In the most advanced fields of stem cell therapy and gene therapy, the number of clinical studies being conducted puts China and the USA in the top two positions globally. The equal number of clinical studies between China and the USA marks the transition of Chinese innovative drugs from "catching up" to "keeping pace with" and even "leading". In this process, the frequent clinical achievements of domestic enterprises and enhanced policy support are propelling the Industry into a rapid development phase.
Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc.
Fosun International Unit to Boost Stake in Henlius Biotech
Hong Kong stocks movement | HENLIUS (02696) rises again by over 9% as FOSUN PHARMA plans to increase its shareholding of HENLIUS by 3.87% for 0.517 billion HKD.
HENLIUS (02696) rose more than 9% again, as of the time of writing, it increased by 8.54%, reaching 36.85 Hong Kong dollars, with a transaction amount of 35.2823 million Hong Kong dollars.
After the unsuccessful privatization of HENLIUS, FOSUN PHARMA took action to increase its Shareholding. Is it continuing to send Bullish signals? | Quick read of the announcement.
① After the privatization failure last year, FOSUN PHARMA continues to signal its bullish outlook on HENLIUS, and today increased its shareholding in HENLIUS; ② HENLIUS had impressive performance last year, and recently has been actively releasing positive news.
FOSUN INTL (00656) increased its Shareholding in HENLIUS (02696) by a total of 3.87%.
FOSUN INTL (00656) announced that on April 17, 2025, FOSUN PHARMA industry (the company through FOSUN...
